Renaissance Health Care Awarded Full Accreditation from NCQA and URAC, and Announces Company Name Change to KidneyTel®

Renaissance Health Care, Inc. (Renaissance) today announced that the National Committee on Quality Assurance (NCQA) has awarded to Renaissance "Full Accreditation Patient and Practitioner Oriented Disease Management for Chronic Kidney Disease." Renaissance also announces that it has received Certification of "Full Accreditation for compliance with Disease Management Standards,” from the Utilization Review Accreditation Committee (URAC) covering the condition of chronic kidney disease.

Renaissance’s President, Robert Farrell, commented, "Renaissance Health Care is very proud to receive full accreditation from these two prestigious accrediting bodies. These accreditations are a validation of the continuous quality improvements in technology, care integration processes, and evidence based medicine policies that Renaissance has put in place to improve the lives of patients with chronic kidney disease. In coordination with the upcoming launch of our new TeleHealth monitoring technology to provide care every day for the kidney patient, Renaissance is changing its name and will now do business as KidneyTel®.”

About Renaissance Health Care, Inc. (d/b/a KidneyTel®)

KidneyTel® is the leading provider of Integrated Care Management services for patients who suffer from chronic kidney disease (CKD). For more information on KidneyTel®, visit www.kidneytel.com. KidneyTel® is a wholly-owned subsidiary of Fresenius Medical Care North America, which is a subsidiary of Fresenius Medical Care AG & Co. KGaA, the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,770,000 individuals worldwide. Through its network of 2,448 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 187,476 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS-p).

For more information about Fresenius Medical Care, visit the company’s websites: www.fmcna.com or www.fmc-ag.com.